Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma

被引:9
作者
Mak, Lung-Yi [1 ]
Ko, Kwan-Lung [1 ]
To, Wai-Pan [1 ]
Wong, Danny Ka-Ho [1 ,2 ]
Seto, Wai-Kay [1 ,2 ,3 ]
Fung, James [1 ,2 ]
Yuen, Man-Fung [1 ,2 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam Rd 102, Hong Kong, Peoples R China
[2] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China
[3] Univ Hong Kong, Dept Med, Shenzhen Hosp, Shenzhen, Peoples R China
关键词
Entecavir; Hepatocellular carcinoma; Hepatitis B core-related antigen; Chronic hepatitis B; RISK; DNA;
D O I
10.5009/gnl19434
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of HBcrAg in entecavir (ETV)-treated CHB patients with subsequent HCC development. We identified HCC cases diagnosed at >= 1 year after ETV initiation. CHB patients without HCC (matched for age, sex, cirrhosis status, baseline hepatitis B virus [HBV] DNA level, and ETV treatment duration) were identified as controls at an HCC:non-HCC ratio of 1:2. Serum samples were retrieved at baseline (ETV initiation) and at 3 and 5 years of ETV therapy for HBcrAg measurement (log IU/mL). In total, 180 patients (60 HCC patients matched with 120 CHB patients without HCC; median age, 56.5 years; 80.6% male; baseline HBV DNA, 5.9 log IU/mL; median follow-up, 6.8 years) were recruited. The median time from ETV initiation to HCC development was 3.2 years. HBcrAg levels were higher in HCC cases than in controls at all three time points: 5.69 log IU/ mL versus 5.02 log IU/mL (p=0.025), 4.23 log IU/mL versus 3.36 log IU/mL (p=0.007), and 3.86 log IU/mL versus 3.36 log IU/mL (p=0.009), respectively. ETV led to similar rates of decline in HBcrAg from baseline to 3 years in both groups (0.34 log IU/mL/year vs 0.39 log IU/mL/year, p=0.774), although the decline from 3 to 5 years was slower in the nonHCC group (0.05 log IU/mL/year) than in the HCC group (0.09 log IU/mL/year, p=0.055). ETV time-dependently reduced HBcrAg in HCC and non-HCC patients. HBcrAg interpretation should consider the antiviral treatment duration.
引用
收藏
页码:665 / 668
页数:4
相关论文
共 15 条
[1]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[2]   Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy [J].
Cheung, K. -S. ;
Seto, W. -K. ;
Wong, D. K. -H. ;
Lai, C. -L. ;
Yuen, M. -F. .
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (08) :654-661
[3]   EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].
Lampertico P. ;
Agarwal K. ;
Berg T. ;
Buti M. ;
Janssen H.L.A. ;
Papatheodoridis G. ;
Zoulim F. ;
Tacke F. .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398
[4]   Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma [J].
Honda, Masao ;
Shirasaki, Takayoshi ;
Terashima, Takeshi ;
Kawaguchi, Kazunori ;
Nakamura, Mikiko ;
Oishi, Naoki ;
Wang, Xuyang ;
Shimakami, Tetsuro ;
Okada, Hikari ;
Arai, Kuniaki ;
Yamashita, Taro ;
Sakai, Yoshio ;
Yamashita, Tatsuya ;
Mizukoshi, Eishiro ;
Kaneko, Shuichi .
JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (07) :1096-1106
[5]   Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues [J].
Hosaka, Tetsuya ;
Suzuki, Fumitaka ;
Kobayashi, Masahiro ;
Fujiyama, Shunichirou ;
Kawamura, Yusuke ;
Sezaki, Hitomi ;
Akuta, Norio ;
Suzuki, Yoshiyuki ;
Saitoh, Satoshi ;
Arase, Yasuji ;
Ikeda, Kenji ;
Kobayashi, Mariko ;
Kumada, Hiromitsu .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (04) :457-471
[6]   Long-Term Entecavir Treatment Reduces Hepatocellular Carcinoma Incidence in Patients With Hepatitis B Virus Infection [J].
Hosaka, Tetsuya ;
Suzuki, Fumitaka ;
Kobayashi, Masahiro ;
Seko, Yuya ;
Kawamura, Yusuke ;
Sezaki, Hitomi ;
Akuta, Norio ;
Suzuki, Yoshiyuki ;
Saitoh, Satoshi ;
Arase, Yasuji ;
Ikeda, Kenji ;
Kobayashi, Mariko ;
Kumada, Hiromitsu .
HEPATOLOGY, 2013, 58 (01) :98-107
[7]   Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B [J].
Lai, Ching-Lung ;
Wong, Danny ;
Ip, Philip ;
Kopaniszen, Malgorzata ;
Seto, Wai-Kay ;
Fung, James ;
Huang, Fung-Yu ;
Lee, Brian ;
Cullaro, Giuseppe ;
Chong, Chun Kong ;
Wu, Ringo ;
Cheng, Charles ;
Yuen, John ;
Ngai, Vincent ;
Yuen, Man-Fung .
JOURNAL OF HEPATOLOGY, 2017, 66 (02) :275-281
[8]   Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels [J].
Lam, Yuk-Fai ;
Seto, Wai-Kay ;
Wong, Danny ;
Cheung, Ka-Shing ;
Fung, James ;
Mak, Lung-Yi ;
Yuen, John ;
Chong, Chun-Kong ;
Lai, Ching-Lung ;
Yuen, Man-Fung .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2017, 8
[9]   Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy [J].
Papatheodoridis, George V. ;
Chan, Henry Lik-Yuen ;
Hansen, Bettina E. ;
Janssen, Harry L. A. ;
Lampertico, Pietro .
JOURNAL OF HEPATOLOGY, 2015, 62 (04) :956-967
[10]   Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study [J].
Papatheodoridis, George V. ;
Manolakopoulos, Spilios ;
Touloumi, Giota ;
Vourli, Georgia ;
Raptopoulou-Gigi, Maria ;
Vafiadis-Zoumbouli, Irini ;
Vasiliadis, Themistoklis ;
Mimidis, Kostas ;
Gogos, Charalambos ;
Ketikoglou, Ioannis ;
Manesis, Emanuel K. .
GUT, 2011, 60 (08) :1109-1116